The global gene transfer technologies market is anticipated to reach USD 5.93 billion in 2029 from USD 3.73 billion in 2024, with a significant CAGR of 9.7%. Major growth drivers of the market are seen in the increasing demand for personalized medicine and cell and gene therapies, investments in gene therapy research, expanding applications in vaccine development, and in cancer immunotherapy.
The market for gene transfer technologies market is competitive. Prominent players in the gene transfer technologiesmarket are Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Qiagen (Netherlands), Sartorius AG (Germany), Bio-Rad Laboratories Inc. (US), Revvity (US), Agilent Technologies, Inc (US), Genscript (US) and Bio-Techne (US) and among others.
To know about the assumptions considered for the study download the pdf brochure
Thermo Fisher Scientific is one of the leaders in gene transfer technologieswith extensive product range. The major strengths of the company include diversified product portfolio, strong geographic presence, adoption of organic & inorganic growth strategies and strong emphasis on launching new products in the market contributes to maintaining its dominant position. For instance, in November 2022, Thermo Fisher launched the Gibco CTS AAV-MAX Helper-Free AAV production system to meet clinical and commercial demands for cost-effective and scalable development of adeno-associated virus (AAV)-based gene therapies.
Danaher Corporation is one of the dominant players in the global gene transfer technologiesmarket, The company offers various gene transfer technologiesthrough its subsidiary, Cytiva. The company became one of the key players in the biotechnology industry by acquiring Pall Corporation in August 2015 for USD 13.8 billion and the Biopharma business (Cytiva) of GE Healthcare in March 2020 for USD 21 billion. The company focuses on strategic alliances, mergers, and new product introduction. For example, in September 2024, Danaher unveiled the RNA delivery LNP kit specifically designed for use with the NanoAssemblr Ignite and Ignite+ systems, which expands the GenVoy-ILM product line to speed mRNA and saRNA vaccine development.
Merck KGaA is also one of the leading firm in gene transfer technologiesmarket. The company operates in the gene transfer technologiesmarket through its life science business segment. The company’s leading position is attributable to its diversified product portfolio, strong geographic presence, and adoption of organic and inorganic growth strategies. For instance, in August 2024, Merck KGaA acquired Mirus Bio (US) to advance Merck’s integrated offering for viral vector manufacturing.
Related Reports:
Gene Transfer Technologies Market by Product (Instruments, Kits, Assays), Mode (Viral (Retrovirus, Adenovirus, AAV), Non-viral (Electroporation, Gene Gun)), Method (In-Vivo, In-vitro), Application, (Gene Therapy, Research) - Global Forecast to 2029
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE